I sold my Ginkgo today. I like the company but... Most of their revenue is stock in affiliated companies. I don't think they have a real business today, and the valuation is insane.
Amyris actually has a synthetic biology business. It's less flashy but it's real.
SPAC's are incredibly risky. When they IPO they basically are shell companies with no operating revenue. So their valuations are essentially fake (some get better market caps because the people who create them have "track records"). Once a startup converts into them their valuation becomes much more interesting. It's a huge gamble. A SPAC that hasn't converted yet is essentially a guessing game. If the SPAC is valued at $500M pre conversion and the market doesn't think the company is worth $500M then you can lose a lot. The opposite is also true.
Note - its much more complex than this, but this is the general idea.
And I think it's pretty random which ones have lock-ups and which ones do not. Generally speaking their lockups are more liberal than traditional IPOs, correct? So it may depend on how disciplined the company's large shareholders are.
Amyris actually has a synthetic biology business. It's less flashy but it's real.